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Effect of laparoscopic sleeve gastrectomy on static and dynamic measures of 
glucose homeostasis and incretin hormone response 4 years post-operatively 
Min T, Prior SL, Churm R, Dunseath GJ, Barry JD, Stephens JW 
 
Abstract  
There is limited literature available on the long-term effect of bariatric surgery especially 
laparoscopic sleeve gastrectomy (LSG) on the incretin hormone response.  
Our primary aim was to investigate changes in glucose metabolism and incretin hormone 
responses in participants with impaired glucose regulation approximately 4 years after LSG. 
The secondary aim was to examine the long-term incretin hormone changes of 
biliopancreatic diversion (BPD).  
A non-randomized prospective study comprising of 10 participants undergoing LSG and 6 
participants undergoing BPD. Serial measurements of glucose, insulin, C-peptide, glucagon 
like peptide -1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) were 
performed during an oral glucose tolerance test pre-operatively and 1 month, 6 months and 
at approximately 4-7 years post-operatively. Area under the curve (AUC) were examined at 
60 and 120 minutes. 
In the LSG group, a significant reduction in 2-hr plasma glucose (2hr PG), HbA1c, and HOMA-
IR was observed at 4 years. Compared with pre-operative levels, significant increases in 
post-glucose GLP-1 secretion were observed at 1 and 6 months, but not maintained at 4 
years. A linear increase was seen in post-glucose GIP response at 1-month and 6-months 
and 4-years. Within the BPD group, a reduction in HbA1c along with an increase GLP-1 
response was observed at 7 years.  
An increase in GLP-1 response was not preserved at 4 years, but a significant increase in GIP 
response was observed along with improved glycaemic control following LSG. 
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Introduction 
Recent years have seen a marked increase in the number of laparoscopic sleeve 
gastrectomy (LSG) operations performed for obesity and obesity associated type 2 diabetes 
(T2DM) [1, 2]. Previous studies have shown that LSG produces weight loss and an 
improvement in metabolic outcomes comparable to Biliopancreatic Diversion (BPD) and 
Roux-en-Y Gastric Bypass (RYGB). A meta-analysis of 11 randomised clinical trials (RCTs), 
comprising of 765 participants, comparing at least 2 of 3 bariatric surgical procedures (LSG, 
RYGB and LAGB) concluded that RYGB and LSG results in similar weight loss, both of which 
were superior to LAGB [3]. Tsoli et al, demonstrated that LSG (n=12) was comparable to BPD 
(n=12) in % Excess weight loss (%EWL), diabetes remission and enhanced postprandial 
Glucagon-like peptide-1 (GLP-1) response at 1 year in patients with obesity associated T2DM 
[4]. Similarly, Nosso et al reported that LSG (n=19) was comparable to RYGB (n=14) in weight 
loss and diabetes remission rate, but the improvement in the postoperative postprandial 
GLP-1 response was more pronounced in the RYGB group at 1 year. [5].  While the 
observations on the effect of LSG on GLP-1 response were consistent with previous studies, 
the data on GIP response remains inconclusive. Some studies have described no changes in 
GIP response [6] while others have reported a decrease [5]. It is important to note that in all 
the published studies relating to LSG, the follow-up period was up to 1 year. There is limited 
literature on the long-term effect of LSG on glucose homeostasis, GLP-1 and GIP response in 
individuals with T2DM or impaired glucose tolerance. 
Previously we have demonstrated that LSG was associated with an improvement in glucose 
homeostasis and an increased GLP-1 response at 1- and 6-months and these results were 
comparable to the BPD group [6]. We hypothesise that these improvements would be 
preserved in the longer term (approximately 4 years). The primary aim of this current study 
was to examine static and dynamic changes in glucose, insulin, C-peptide, GLP-1 and GIP in 
participants with T2DM and impaired glucose regulation at a mean follow-up period of 4 
years after LSG. The secondary aim was to examine long-term incretin hormone changes in 




Approval for the study was obtained from the Local Research Ethics Committee (LREC 
reference 06/WMW02/7). Participants (n=40) who took part in a previously published initial 
study [6] (pre-operative, 1-month and 6-month post-operative) were invited (by post, email 
or telephone call) to return at a mean follow-up of 4 years (range: 2-7 years). There were 26 
participants in the LSG group and 14 in the BPD group. Ten participants in the LSG group and 
6 in the BPD group agreed to participate. Sixteen particpants in LSG group and 2 in the BPD 
group were lost to follow-up or declined to participate in the follow-up study. Six 
participants were deceased in the BPD group. The study sample has been previously 
described [6, 7]. In brief, the inclusion criteria at the outset included: - both gender, age 
between 20 and 60 years and BMI ≥40 kg/m2. All participants had previously diagnosed 
T2DM or diagnosed during an Oral Glucose Tolerance Test (OGTT) at the start of the study 
or impaired glucose regulation according to the American Diabetes Association (ADA) 
criteria [8]. Buse’s consensus (2009) criteria was used to define diabetes remission [9]. 
Complete remission is defined as HbA1c <6% and fasting plasma glucose (FPG) <5.6 mmol/L 
and off medication and partial remission is defined as HbA1c 6.0-6.4% and FPG 5.6-6.9 
mmol/L and off medication for 1 year.  
 
Study design 
The study was a non-randomised prospective study. All the participants underwent a 
standardised 75 g OGTT (122 mls of Polycal 61.9 g/ 100 ml of glucose, Nutricia Clinical Care, 
Trowbridge, UK) pre-operatively and post-operatively at 1 month, 6 months and 4 years. 
Pre-operative tests were performed 1 month prior to the surgery. All participants were 
asked to fast from the midnight before the test and all diabetes related medications were 
omitted for 24 hours before OGTT. During the OGTT, blood samples were collected for 
measurements of glucose, insulin, C-peptide, GLP-1 and GIP at time 0, 15, 30, 45, 60 and 120 
minutes. All samples were collected on ice, centrifuged within one hour of collection and 
stored at -800C until analysis. At the time of the pre-operative and post-operative OGTT, 
clinical and biochemical information were obtained. Clinical measurements included weight, 
height, body mass index (BMI), waist circumference and blood pressure. Biochemical data 
such as HbA1c and lipid profile were analysed within the local hospital accredited 
laboratory.  
 
Measurement of insulin, C-peptide, insulin sensitivity and beta cell function 
Insulin was measured using an Invitron Insulin ELISA kit. The analytical sensitivity of the 
Invitron insulin assay was 0.02 mU/L and the dynamic range of this assay is 0.02 – 250 mU/L. 
The inter-assay coefficient of variation was ≤7.1. Cross reactivities (CR) of related proteins 
were as follow: - CR 1.2% with intact proinsulin; and 0% with C-peptide. C-peptide was 
measured with an Invitron C-peptide kit. The analytical sensitivity of the Invitron C-peptide 
assay was 5.0 pmol/L. The dynamic range of this assay is 5.0-5,000 pmol/L. There was 2% 
cross reactivity with intact proinsulin but no cross reactivity with insulin.  
 
Insulin sensitivity and beta cell function was measured with Homeostasis Model Assessment 
(HOMA) by using measurements of fasting glucose and C-peptide concentrations. These 
were calculated by using the Oxford University online calculator 
(https://www.dtu.ox.ac.uk/homacalculator/ accessed 01 June 2015). HOMA was first 
developed by Matthews and colleagues in 1985 [10] and updated to a HOMA2 computer 
model in 1996 [11]. HOMA provides three measures: HOMA-%B (estimated steady state 
beta cell function), HOMA-%S (insulin sensitivity) and HOMA-IR (insulin resistance). These 
measures have been validated and shown to correlate with clamp-derived studies [11].  
 
Measurement of total GLP-1 and total GIP 
Total GLP-1 was quantitatively measured using the EMD Millipore Total GLP-1 ELISA Kit. The 
antibody pair used in this assay measures GLP-1 (7-36) and (9-36) and has no significant 
cross-reactivity with GLP-2, GIP, Glucagon and Oxyntomodulin. The sensitivity of this assay 
was 1.5 pM and the approximate range of this assay was 4.1 to 1,000 pM. The intra- and 
inter-assay coefficients of variation were ≤2% and ≤12% respectively. Total GIP was 
measured using the EMD Millipore Human GIP (total) ELISA Kit, which reacts fully with intact 
GIP (1-42) and the NH2-terminally truncated metabolite GIP (3-42). The assay does not 
significantly cross-react with Glucagon, Oxyntomodulin, GLP-1 and GLP-2. The sensitivity of 
this assay was 4.2 pg/mL (20 μL sample size). The appropriate range of this assay is 4.2 
pg/mL to 2,000 pg/mL.  The intra- and inter-assay coefficients of variation were ≤8.8% and 
≤6.1% respectively.  
 
Statistical analysis 
Statistical analysis was performed using SPSS (version 22, SPSS Inc., Chicago). The normality 
of data was assessed by the Shapiro-Wilk test. Continuous data with a normal distribution 
are presented as mean and standard deviation, and data that did not have a normal 
distribution are described as median and interquartile range. We used ANOVA with post-hoc 
analyses for data with a normal distribution and Friedman test for data without a normal 




There were 10 participants (6 Females, a mean age of 52 ±6 years) in the LSG group and 6 (5 
Females, a mean age of 48 ±7 years) in the BPD group with follow-up data available for 
analysis. The mean duration of follow-up for the LSG group was 4.0 ± 1.5 years and for the 
BPD group 7.2 ± 0.6 years. The baseline and follow-up characteristics of both groups are 
shown in Table 1. Eight participants had T2DM in the LSG group and all 6 participants in the 
BPD group. The median duration of T2DM was 19 months in the LSG group and 41 months 
in the BPD group.  
 
Changes in weight, blood pressure and lipid profile 
In both the LSG and BPD groups, an initial improvement in clinical measures of obesity at 1 
and 6 months were maintained at long-term follow-up (Table 1). A reduction in both systolic 
and diastolic blood pressure was noted at 4 years in the LSG group. There was a significant 
increase in total cholesterol and LDL-cholesterol along with HDL-cholesterol following LSG 
whereas a reduction in total cholesterol, LDL-cholesterol and HDL-cholesterol was observed 
following BPD. However, triglyceride level in both groups did not show any significant 
changes.  
 
Changes in glucose-insulin homeostasis  
LSG group 
FPG level was lower at 4 years compared to baseline but the result did not reach statistical 
significance. 2-hour plasma glucose (2hr PG) and HbA1c were significantly lowered at 4 
years compared to baseline. Four participants (50%) (1 complete +3 partial) achieved 
remission of T2DM at 4 years. Preoperatively, two participants were treated with insulin and 
three treated with oral diabetes agents/ GLP-1 agonist. Postoperatively, one received insulin 
and two received oral diabetes agents. None of these participants were on long-acting oral 
diabetes agents. Fasting insulin, 2hr insulin ,fasting C-peptide and 2hr C-peptide levels were 
lower at 4 years but did not reach statistical significance. A significant reduction in HOMA-IR 
and HOMA-%B and a significant increase in HOMA-%S were observed (Table 2). 
BPD group 
There was no change in FPG at 7 years. However, a reduction in 2hr PG and HbA1c were 
observed. Two participants (33%) achieved complete diabetes remission. Two out of 6 
participants were on oral agents postoperatively, whereas all received oral diabetes agents 
preoperatively. A numerical but non-significant reduction in fasting insulin, 2 hr insulin and 
HOMA-%IR and a non-significant increase in HOMA-%B and HOMA-%S were observed at 7 
years. There was no change in fasting C-peptide and 2-hour C-peptide at 7 years (Table 2). 
 
Dynamic measurements of glucose, insulin and C-peptide 
LSG group 
At 4 years, there was a significant reduction in the mean plasma glucose at 120 minutes but 
not at 0, 15, 30, 45, and 60 minutes. The peak glucose response was shifted to the left (peak 
at 45 minutes at 4 years and at 60 minutes at baseline) (Figure 1). The median AUC 
measurements for glucose did not show any significant changes compared to baseline 
(Table 3). With respect to dynamic insulin changes, there were no significant changes in the 
mean insulin at all 6 time points as well as the AUC measurements (AUC 0-60, AUC 0-120). The 




At 7 years, there was a significant reduction in the mean plasma glucose at 120 minutes but 
not at the remaining time points. The peak glucose response was shifted to the left (peak at 
30 minutes at 7 years, and at 60 minutes at baseline) (Figure 1). The median AUC 
measurements of glucose did not show any significant changes compared to baseline. There 
were also no changes in AUC measurements of insulin and C-peptide at 7 years. The BPD 
group had significant lower C-peptide AUC measurements compared to the LSG group pre-
operatively, 1 and 6 month and 7 years post-operatively (Table 3).  
 
Changes in incretin hormones  
LSG group 
Fasting GLP-1 concentrations were not different at 4 years compared to baseline (Table 2). A 
significant increase in postprandial GLP-1 responses achieved at 1 and 6 months was not 
observed at 4 years. There were no changes in the GLP-1 AUC 0-60 and AUC 0-120 at 4 years 
postoperatively (Table 3). On the other hand, a non-significant increase in fasting GIP and 
postprandial GIP responses were observed at 4 years. There was a significant increase in the 
mean GIP concentrations at all postprandial sampling time points at 4 years, in contrast to 
1- and 6-months (Figure 1). In line with this, there were significant increase in the GIP AUC 0-
60 and non-significant increase in the GIP AUC 0-120 at 4 years postoperatively. 
 
BPD group 
There was a significant increase in fasting GLP-1 at 7 years but there was no change in 
fasting GIP (Table 2). A significant increase in postprandial GLP-1 response was observed at 
7 years compared to baseline. However, there was no significant changes in GIP response 
(Table 3 and Figure 1).  
 
Discussion 
LSG has become a popular bariatric surgical procedure due to its comparable effectiveness 
and safety profile. In line with previous studies [3, 12-15], we observed significant 
improvements in markers of glycaemia as well as a significant weight loss at 4 years. There 
was a significant reduction in HbA1c and 2hr PG levels. One of eight participants achieved 
complete diabetes remission. The complete remission rate in our study is comparable to 
other published studies using ADA criteria. Mingrone et al, reported 0% complete remission 
rate 5 years after RYGB (n=19) and BPD (n=19) [16]. Previous studies have shown that LSG 
has no significant impact on lowering total cholesterol and LDL-C but is associated with an 
increase in HDL-C [17-19]. Van Osdal et al, showed that the proportion of participants with a 
total cholesterol concentration [≥200 mg/dL (5.2 mmol/L)] and LDL-C concentration values 
[≥130 mg/dL (3.4 mmol/L)] was greater in the LSG group than the RYGB group (30% vs 10%, 
p<0.001 for total cholesterol; 24% vs 4%, p,0.001 for LDL-C). They also observed that the LSG 
group had higher proportion of patients with the recommended HDL-C values than the 
RYGB group (57% vs 52%, p=0.68) [19]. In our study, there was a significant increase in LDL-C 
and HDL-C at 4 years. Regarding triglyceride level, which is related to the degree of weight 
loss, we did not find any significant changes despite a significant weight loss at 4 years. 
Along with a significant weight loss, we observed a non- significant reduction in fasting C-
peptide and fasting insulin. Of note, elevated levels of fasting insulin and C-peptide are a key 
feature of individuals with insulin resistance [11]. Previous studies have demonstrated that 
LSG is associated with a reduction in insulin resistance [20]. In line with this, we observed a 
significant improvement in insulin sensitivity (reduction in insulin resistance) at 1 and 6 
months. At 4 years, insulin sensitivity (HOMA%-S) decreased compared to the 1- and 6-
month’s values but was still greater than the baseline level. Similarly, insulin resistance  as 
measured by HOMA-IR increased by 4 years but remained lower than the baseline value. 
These observations might be explained by weight regained at 4 years (mean BMI was 36.9 
kg/m2 at 6 months and 39.1 kg/m2 at 4 years). With respect to the effect of bariatric surgery 
on beta cell function, previous studies have demonstrated an improvement in beta cell 
function in the early post-operative period [21] but limited improvement in the long-term 
[22].  In line with this, we observed a significant increase in HOMA-%B at 1 and 6 months, 
but a significant decrease at 4 years and a downward trend of HOMA-%B from 1-month 
post-operatively to 4-year post-operatively.  
 
With respect to BPD, our observations of improvement in measures of obesity, glycaemic 
control, fasting GLP-1 and postprandial GLP-1 responses were in line with previous 
published literature. Since BPD is a malabsorptive procedure, it is associated with a 
significant improvement in lipid profile. In line with this, we observed a significant decrease 
in total cholesterol at 1 month, 6 months, 7 years and LDL-cholesterol at 1 month and 6 
months.  
 
While there is abundant evidence on the metabolic outcomes of LSG, there is limited 
literature available on the detailed examination of long-term effect of LSG on glucose 
metabolism and incretin hormone response. Most clinical studies have follow-up periods 
between 6 weeks and 12 months [4, 13, 23]. Our previous study described a significant 
improvement in static and dynamic measurements of glucose at 1 and 6 months in 22 
participants with impaired glucose regulation [6]. In the current study, we observed a 
reduction in 2hr PG and HbA1c but no significant changes in glucose AUC measurements in 
both groups. The mean plasma glucose concentrations at all postprandial sampling time 
points except 120 minutes were not different at 4 years compared to baseline. The AUC 
measurements for glucose (0-60min) (0-120min) did not show any significant changes, suggesting 
that the glucose intolerance state of the participants at 4 years was similar to baseline. Time 
related relapse of T2DM following bariatric surgery is inevitable [24]. This study’s 
observations raised the questions of whether the glucose AUC measurements are better 
than static glucose measurements to detect impaired glucose regulation? Of interest, 
published studies have suggested that the 2hr PG alone cannot predict the full picture of 
glucose intolerance and the glucose AUC measures are better than 2hr PG [25].  
 
Both LSG and BPD are associated with an accelerated gastric emptying [26]. Studies have 
suggested that gastric emptying time has an impact on glucose homeostasis and is related 
to the peak circulation glucose contraction after an oral glucose load. The higher initial 
gastric emptying rate is positively correlated with the peak postprandial glucose 
concentration [27]. In line with this, we observed that the peak glucose response was 
shifted to the left in both LSG and BPD group. The time to reach peak glucose concentration 
after an oral glucose load was 60 minutes in both groups at baseline and 45 minutes in the 
LSG group and 30 minutes in the BPD group at long-term follow-up visit. 
 
An enhanced GLP-1 response is thought to be one of the mechanisms responsible for the 
resolution of T2DM following bariatric surgery [28, 29]. Previous studies demonstrated that 
LSG results in an increased GLP-1 response and a T2DM complete remission rate 
comparable to BPD [4] and RYGB [12]. Tsoli et al, reported that both BPD and LSG are 
associated with an increase GLP-1 response at 1 month, 3 month and 12 months in 24 
participants with T2DM [4]. Papamargaritis et al, reported that the postprandial GLP-1 
responses were significantly increased at 6 weeks following LSG and remained at this level 
at 1 year [30]. In contrast to previous observations of studies with short-term follow-up, 
there were no significant changes in fasting and postprandial GLP-1 responses in the LSG 
group at 4 years. One of the possible explanations for our findings is a type 2 error. The 
other possible explanation is the use of an OGTT instead of a mixed meal tolerance test. The 
majority of previous published studies have measured a meal-stimulated GLP-1 [5, 12, 13], 
while others have examined glucose-stimulated GLP-1 [4, 6] Of interest, Nannipieri and 
colleagues reported an increased GLP-1 response at 15 days but an attenuated GLP-1 
response at 1 year following RYGB (n=23) and LSG (n=12) in patients with T2DM [13]. This 
study used a mixed meal test. Our findings question the role of GLP-1 in the mechanism of 
long-term diabetes remission. Of note, Steven and colleagues reported that calorie 
restriction but not GLP-1 explains the acute improvement in glycaemic control following 
RYGB in subjects with T2DM [31].  
 
With regard to GIP, an increase in fasting GIP as well as postprandial GIP response was 
observed in the LSG group at 4 years. However, there was no significant changes in GIP 
response at 1 month and 6 months. Previous studies have described conflicting observations 
on the GIP response following LSG. Some studies have described no changes in GIP response 
[6] while others have reported a decrease [5]. On note, these studies examining GIP 
response have follow-up period of up to 12 months only. The findings of our current study 
suggest that GIP might play a role in the long-term diabetes outcome.  
 
Although GLP-1 and GIP are derived from the intestine, they have different sites of secretion 
within the gut: GLP-1 is mainly secreted from ileal L-cells, while GIP is secreted from the K-
cells of the duodenum and jejunum. There might be differences in GLP-1 and GIP responses 
relating to changes in gut anatomy following different bariatric procedures [29]. Our study 
showed that the BPD group maintained the improvement in GLP-1 response at 7 years, 
while the LSG group showed no change at 4 years from baseline. Of importance, BPD 
involves considerable alteration in the anatomy of the gut, which may result in direct 
exposure of nutrients to the ileal L-cells and would therefore produce a greater post-
prandial GLP-1 response compared to LSG. On the other hand, LSG would produce a greater 
post-prandial GIP response because of the expedited delivery of nutrient to the duodenum 
and the jejunum where K-cells are populated. In line with this, a greater GIP response was 
observed in the LSG group at 4 years.  
 
To our knowledge, our study is the first to examine the glucose, incretin hormone response 
4 years after LSG in participants with impaired glucose regulation. We describe the novel 
findings of no change in GLP-1 response but an exaggerated GIP response along with an 
improvement in glycaemic control at 4 years following LSG. These observations require 
replication in other bariatric cohorts with longer follow-up.  
 
There are limitations to the current study. Firstly, our study had a small sample size, 
particularly for the BPD group. The second limitation was that there was a considerable 
drop-out rate at long-term follow-up with 22.5% (18/40) of participants declining to take 
part or being lost to follow-up, and 15% (6/40)  were deceased. We have examined whether 
the pre-operative clinical and biochemical characteristics of the participants were related to 
their long-term follow-up attendance and survival status. There were no differences in 
baseline weight, blood pressure, HbA1c and lipid profile (except triglyceride level) amongst 
those who participated in the study, compared to those who were lost-to-follow-up and 
deceased. All 6 deceased participants underwent BPD, had a significant higher level of 
triglyceride and lower fasting C-peptide. The causes of death were infection (n=3), suicide 
(n=1) and unknown (n=2). The third limitation was a variation in follow-up duration in two 
groups. The BPD group had longer follow-up than the LSG group. Despite this, we observed 
that the BPD group had a significant increase in GLP-1 level compared to baseline, whereas 
the LSG group had no change in GLP-1 level. The fourth limitation was the study design, 
which was a nonrandomised prospective study. At the time of initial study, participants who 
had BMI >50 kg/m2 were usually offered BPD as per local protocol. Within the current study 
we did not plan at the outset to measure glucagon and other gut hormones such as ghrelin, 
neuropeptide Y.  
 
Conclusion 
The current study supports the role of LSG in the management of obesity associated T2DM 
in the long-term. Despite a non-significant weight regain, increase in HbA1c and a decline in 
HOMA measures compared to the 6-month values, the study observed that LSG was 
associated with a significant reduction in weight and glycaemic measures compared to 
baseline values. This work also provides new insight relating to the long-term effect of LSG 
on incretin hormone responses, which requires further evaluation.   
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Table 1: Weight, blood pressure and lipid profile pre-operatively and 1, 6 months and 4-7 
years after LSG and BPD  
Baseline 1 month 6 months 
4 years (LSG) 
7 years (BPD) 
P 
Weight (kg)      
LSG 135 ±29 118 ±27 102 ±20 107 ±28 0.001 
BPD 184 ±36 162 ±28 143 ±26 134 ±16 0.003  
     
BMI (kg/m2)      
LSG 48.4 ±7.2 42.7 ±7.1 36.9 ±6.8 39.1 ±9.6 0.001 
BPD 69.5 ±15.0 60.8 ±11.5 54.7 ±9.0 52.9 ±10.0 0.024  
     
%EWL      
LSG  27 ±10 50 ±19 46 ±28  
BPD  19 ±7 35 ±9 40 ±12  
      
SBP (mmHg)      
LSG 143 ±31 122 ±17 129 ±20 130 ±26 NS 
BPD 127 ±17 127 ±10 135 ±9 131 ±14 NS  
     
DBP (mmHg)      
LSG 83 ±19 72 ±10 75 ±9 78 ±15 NS 
BPD 80 ±3 67 ±5 78 ±5 68 ±10 NS  
     
TC (mmol/L)      
LSG 4.1 ±0.6 4.3 ±1.2 4.9 ±1.3 5.4 ±1.1 0.009 
BPD 4.4 ±1.2 3.1 ±0.6 3.1 ±0.5 3.3 ± 0.3 0.005  
     
LDL-C (mmol/L)      
LSG 2.2 ±0.5 2.5 ±0.9 3.0 ±1.0 3.1 ±0.9 0.027 
BPD 2.4 ±1.0 1.4 ±0.6 1.3 ±0.4 1.5 ±0.4 0.029  
     
HDL-C (mmol/L)      
LSG 1.3 ±0.4 1.2 ±0.3 1.3 ±0.4 1.7 ±0.6 0.007 
BPD 1.4 ±0.2 1.1 ±0.2 1.1 ±0.1 1.3 ±0.2 0.001  
     
TG (mmol/L)      
LSG 1.5 ±0.6 1.5 ±0.6 1.4 ±0.5 1.5 ±0.6 NS 
BPD 1.5 ±0.6 1.5 ±0.3 1.4 ±0.4 1.1 ±0.3 NS 
Data are presented as mean ±SD. LSG: Laparoscopic sleeve gastrectomy; BPD: Biliopancreatic diversion; BMI: 
body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; LDL-C: low 
density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; TG: triglyceride; NS: non-
significance. 
P value calculated from ANOVA.  
  
Table 2: Static measurements of glucose-insulin homeostasis and incretin hormones in the 
LSG and BPD groups  
Baseline 1 month 6 months 4 years (LSG) 
7 years (BPD) 
P 
FPG (mmol/L) 
    
 
LSG 7.9 ±3.2 5.5 ±0.8 5.5 ±1.4 6.8 ±1.9 0.034 
BPD 7.0 ±1.7 6.1 ±1.5 7.6 ±5.2 7.2 ±3.0 NS 
     
 
2hr PG (mml/L) 
    
 
LSG 12.2 ±6.1 8.3 ±4.7 7.5 ±6.8 9.0 ±4.2 0.050 
BPD 11.4 ±3.1 9.5 ±3.4 12.0 ±8.0 9.0 ±4.6 NS 
     
 
HbA1c (mmol/mol) 
    
 
LSG 55.2 ±19.5 48.9 ±14.1 40.1 ±8.7 45.1 ±9.5 0.050 
BPD 53 ±9 43 ±8 48 ±21 40 ±12 0.001 
     
 
Fasting insulin (mU/L)^ 
   
 
LSG 26 (21-31) 10 (6-18)  10 (5-18) 20 (5-42) NS 
BPD 22 (12-36) 18 (13-27) 14 (7-20) 11 (6-18) NS 
     
 
2hr Insulin (mU/L)^ 
   
 
LSG 105 (44-162) 42 (24-153) 22 (12-170) 55 (22-137) NS 
BPD 55 (25-60) 36 (25-67) 50 (33-76) 41 (23-49) NS 
     
 
Fasting C-Peptide (nmol/L) 
   
 
LSG 1.5 ±0.2 1.3 ±0.4 1.2 ±0.6 0.7 ±0.4 NS 
BPD 0.8 ±0.6 0.9 ±0.3 0.6 ±0.2 0.7 ±0.7 NS 
     
 
2hr C-Peptide (noml/L)      
LSG 3.8 ±1.5 4.1 ±1.7 3.7 ±2.1 2.5 ±1.6 NS 
BPD 1.9 ±1.0 1.5 ±1.0 1.8 ±0.0 1.1 ±0.2 NS 
     
 
HOMA-%B 
    
 
LSG 117 ±17 175 ±19 155 ±25 83 ±15 0.001 
BPD 79 ±36 116 ±61 93 ±38 94 ±90 NS 
      
HOMA-%S^ 
    
 
LSG 31 (22-41) 72 (45-131)  87 (49-200)  43 (21-179) 0.019 
BPD 41 (26-64) 51 (39-62) 80 (43-125) 89 (54-133) NS 
     
 
HOMA-IR^ 
    
 
LSG 3.3 (2.5-4.4) 1.4 (0.8-2.2)  1.2 (0.5-2.0) 2.4 (0.6-5.0) 0.019 
BPD 2.7 (1.5-4.0) 2.0 (1.6-2.9) 1.6 (0.8-2.4) 1.4 (0.7-1.9) NS 
Fasting GLP-1 (pmol/L) 
    
 
LSG 1.9 ±1.7 0.6 ±0.3 0.7 ±0.6 1.3 ±1.3 NS 
BPD 1.1 ±0.8 2.2 ±1.7 1.1 ±1.5 2.9 ±0.9 0.044 
     
 
Fasting GIP (pg/mL) 
    
 
LSG 71 ±36 85 ±36 64 ±41 115 ±37 NS 
BPD 94 ±38 93 ±48 74 ±39 108 ±55 NS 
Data are presented as mean ±SD unless otherwise stated. ^Data are presented as median and interquartile 
range. FPG: Fasting plasma glucose; 2hr PG: 2-hour plasma glucose; HbA1c: Haemoglobin A1c; HOMA-%S: 
homeostatic model assessment (insulin sensitivity); HOMA-IR: homeostatic model assessment (insulin 
resistance); HOMA-%B: homeostatic model assessment (beta cell function); GLP-1: glucagon like peptide-1; 
GIP: glucose dependent insulinotropic polypeptide.  
p value calculated from ANOVA or Friedman test. NS: non-significance. 
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Table 3: Dynamic measurements of glucose, insulin, C-peptide, GLP-1 and GIP within LSG 
and BPD groups 
 Baseline 1 month 6 months 
4 years (LSG) 
7 years (BPD) 
P 
Glucose AUC0-60 (mmol/L/hr)     
LSG 11.5 ±2.9 9.6 ±-0.7 8.8 ±2.5 11.7 ±3.5 NS 
BPD 10.4 ±2.7 7.5 ±1.6* 9.5 ±5.8 10.8 ±3.6 NS 
      
Glucose AUC0-120 (mmol/L/hr)     
LSG 16.2 ±3.5 13.5 ±2.4 12.7 ±4.6 15.6 ±4.5 NS 
BPD 23.1 ±5.6* 15.3 ±3.9 20.1 ±12.4 21.6 ±7.5 NS 
      
Insulin AUC0-60 (mU/L/hr)^     
LSG 72 (39-93) 81 (46-104) 61 (44-119) 83 (64-114) NS 
BPD 61 (25-88) 50 (19-69) 50 (23-80) 40 (32-63) NS 
      
Insulin AUC0-120 (mU/L/hr) ^     
LSG 107 (64-150) 133 (66-155) 67 (59-159) 111 (85-149) NS 
BPD 79 (50-195) 108 (25-134) 74 (34-159) 78 (64-120) NS 
      
C-peptide AUC0-60 (nmol/L/hr)^     
LSG 2.4 (1.6-3.0) 3.6 (2.0-4.4)  2.2 (1.6-3.1) 2.0 (1.6-3.1) NS 
BPD 0.9 (0.4-2.0)* 1.2 (0.3-1.7) * 1.3 (0.9-1.7) * 1.2 (0.8-1.5) * NS 
      
C-peptide AUC0-120 (nmol/L/hr)^     
LSG 3.4 (2.9-4.5) 5.3 (3.1-6.2)  3.3 (2.2-4.3) 2.8 (2.3-4.1) NS 
BPD 2.0 (0.9-2.8) * 2.3 (0.6-3.2) * 2.1 (1.9-3.0) * 2.2 (1.9-3.0)  NS 
      
GLP-1 AUC0-60 (pmol/L/hr)     
LSG 3.7 ±2.7 14.1 ±6.4 15.4 ±8.2 3.0 ±2.8 NS 
BPD 2.9 ±1.6 13.2 ±7.7 9.0 ±7.1 6.2 ±1.6 0.001 
      
GLP-1 AUC0-120 (pmol/L/hr)     
LSG 4.8 ±1.3 18.0 ±8 21.4 ±12.3 4.2 ±4.8 NS 
BPD 4.3 ±2.4 21.0 ±10.6 17.2 ±10.9 10.4 ±2.4* 0.001 
      
GIP AUC0-60 (pg/mL/hr)     
LSG 302 ±112 399 ±145 444 ±128 678 ±358 0.020 
BPD 389 ±206 205 ±98* 230 ±58 388 ±180* NS 
      
GIP AUC0-120 (pg/mL/hr)     
LSG 463 ±307 603 ±366 743 ±654 952 ±591 NS 
BPD 983 ±290 424 ±185 411 ±91 681 ±336 NS 
Data are presented as mean ±SD unless otherwise stated. ^Data are presented as median and interquartile 
range. GLP-1: glucagon like peptide-1; GIP: glucose dependent insulinotropic polypeptide; AUC: area under the 
curve.  





Figure 1: Changes in glucose, insulin, C-peptide, GLP-1 and GIP during the OGTT before and 
1 month, 6 months and 4-7 years after LSG and BPD 
Value represents mean ± Standard error.  GLP-1: glucagon like peptide-1; GIP: glucose 
dependent insulinotropic polypeptide; LSG: laparoscopic sleeve gastrectomy; BPD: 
biliopancreatic diversion. 
